Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry

[1]  G. Canonica,et al.  The Severe Asthma Network in Italy: Findings and Perspectives. , 2019, The journal of allergy and clinical immunology. In practice.

[2]  G. Canonica,et al.  Strategies to reduce corticosteroid-related adverse events in asthma , 2019, Current opinion in allergy and clinical immunology.

[3]  Jonathan D. Campbell,et al.  Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations , 2018, PharmacoEconomics.

[4]  K. Rabe,et al.  Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.

[5]  M. Sadatsafavi,et al.  The projected economic and health burden of sub-optimal asthma control in Canada. , 2018, Respiratory medicine.

[6]  G. Canonica,et al.  Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma. , 2018, Journal of Allergy and Clinical Immunology: In Practice.

[7]  G. Werneck,et al.  Estimativa de custo da asma em tratamento ambulatorial: estudo com dados de mundo real , 2018 .

[8]  T. Nurmagambetov,et al.  The Economic Burden of Asthma in the United States, 2008‐2013 , 2018, Annals of the American Thoracic Society.

[9]  C. Janson,et al.  Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR) , 2018, Respiratory Research.

[10]  Guijing Wang,et al.  Prevalence and Medical Costs of Chronic Diseases Among Adult Medicaid Beneficiaries , 2017, American journal of preventive medicine.

[11]  G. Canonica,et al.  Asthma: personalized and precision medicine , 2017, Current opinion in allergy and clinical immunology.

[12]  A. White,et al.  Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. , 2017, Clinical therapeutics.

[13]  J. Ross,et al.  Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection. , 2017, The journal of allergy and clinical immunology. In practice.

[14]  William H. Yang,et al.  The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study , 2017, PloS one.

[15]  D. Khatry,et al.  Burden of Chronic Oral Corticosteroid Use by Adults with Persistent Asthma. , 2017, The journal of allergy and clinical immunology. In practice.

[16]  L. Heaney,et al.  The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis , 2017, Respiratory Research.

[17]  K. Rabe,et al.  Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.

[18]  G. Canonica,et al.  SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma , 2017, Clinical and Molecular Allergy.

[19]  A. Colao,et al.  Healthcare usage and economic impact of non-treated obesity in Italy: findings from a retrospective administrative and clinical database analysis , 2017, BMJ Open.

[20]  Anand A. Dalal,et al.  Burden of systemic glucocorticoid-related complications in severe asthma , 2017, Current Medical Research and Opinion.

[21]  R. D. Dal Negro,et al.  Cost of persistent asthma in Italy , 2016, Multidisciplinary Respiratory Medicine.

[22]  M. Broder,et al.  Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis , 2016, ClinicoEconomics and outcomes research : CEOR.

[23]  G. Marchesini,et al.  The relative burden of diabetes complications on healthcare costs: The population-based CINECA-SID ARNO Diabetes Observatory. , 2016, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[24]  D. Price,et al.  Determinants and impact of suboptimal asthma control in Europe: The INTERNATIONAL CROSS-SECTIONAL AND LONGITUDINAL ASSESSMENT ON ASTHMA CONTROL (LIAISON) study , 2016, Respiratory Research.

[25]  D. Price,et al.  Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry , 2016, Thorax.

[26]  Anand A. Dalal,et al.  Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. , 2015, The Journal of allergy and clinical immunology.

[27]  D. Lang.  Severe asthma: epidemiology, burden of illness, and heterogeneity. , 2015, Allergy and asthma proceedings.

[28]  S. Cottrell,et al.  Quantifying The Cost And Quality Of Life Implications Of Adverse Events Associated With Long-Term Oral Corticosteroid Use. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[29]  S. Wise,et al.  Epidemiology and economic burden of asthma , 2015, International forum of allergy & rhinology.

[30]  D. Price,et al.  Patient Reported Burden of Asthma on Resource Use and Productivity Across 11 Countries in Europe , 2015, Advances in Therapy.

[31]  A. Zwinderman,et al.  The prevalence of severe refractory asthma. , 2015, The Journal of allergy and clinical immunology.

[32]  C. Porsbjerg,et al.  The prevalence of severe asthma and low asthma control among Danish adults. , 2014, The journal of allergy and clinical immunology. In practice.

[33]  G. Canonica,et al.  Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. , 2014, The Journal of allergy and clinical immunology.

[34]  I. Pavord,et al.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.

[35]  S. Bianchi,et al.  The social cost of chronic kidney disease in Italy , 2014, The European Journal of Health Economics.

[36]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[37]  G. Colombo,et al.  Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy , 2012, ClinicoEconomics and outcomes research : CEOR.

[38]  A. Gulsvik,et al.  The Cost of Persistent Asthma in Europe: An International Population-Based Study in Adults , 2012, International Archives of Allergy and Immunology.

[39]  R. de Marco,et al.  Trends in the prevalence of asthma and allergic rhinitis in Italy between 1991 and 2010 , 2011, European Respiratory Journal.

[40]  L. Crofford,et al.  Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. , 2011, Clinical therapeutics.

[41]  L. Pradelli,et al.  Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. , 2011, European annals of allergy and clinical immunology.

[42]  D. Poetker,et al.  A comprehensive review of the adverse effects of systemic corticosteroids. , 2010, Otolaryngologic clinics of North America.

[43]  A. Cerulli,et al.  The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. , 2009, Respiratory medicine.

[44]  S. Sullivan,et al.  An evaluation of the cost‐effectiveness of omalizumab for the treatment of severe allergic asthma , 2008, Allergy.

[45]  N. Motterlini,et al.  Medical Costs of Glaucoma and Ocular Hypertension in Italian Referral Centres: A Prospective Study , 2007, Ophthalmologica.

[46]  K. Saag,et al.  The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. , 2005, Rheumatology.

[47]  C. Bucca,et al.  Asthma severity and medical resource utilisation , 2004, European Respiratory Journal.

[48]  C. Trevisan,et al.  il costo delle fratture da osteoporosi in italia. Risultati dello studio BloCK ( Bone Loss and Osteoporosis: Cost-of-illness Knowledge) , 2011 .